BRENTWOOD, Tenn. / Jul 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its second quarter 2025 results after the market closes on Tuesday, August 5, 2025. A conference call will be held the following day, Wednesday, August 6, 2025, at 10 a.m. ET to review the company’s financial results, discuss recent events and conduct a question-and-answer session.
A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.
To participate in the live teleconference:
United States Live: | 1-888-596-4144 |
International Live: | 1-646-968-2525 |
Access Code: | 4437657 |
To listen to a replay of the teleconference, which will be available through August 20, 2025:
United States Replay: | 1-800-770-2030 |
International Replay: | 1-609-800-9909 |
Access Code: | 4437657 |
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.
| Last Trade: | US$8.78 |
| Daily Change: | -0.28 -3.09 |
| Daily Volume: | 196,544 |
| Market Cap: | US$1.260B |
November 12, 2025 August 05, 2025 May 06, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load